SONN: Sonnet BioTherapeutics Holdings Inc. Net earnings per share (EPS TTM)

Sonnet BioTherapeutics Holdings (SONN) - corporate logo

Sonnet BioTherapeutics (SONN) relies on a virtual model, outsourcing manufacturing and clinical operations to external partners. The 12-month net income per share trend links this approach to the company's reputation as a developer of innovative cytokine delivery systems. The value of -8.28 indicates the current metric level, while the absence of commercial sales and a focus on early-stage development create high binary risks.

SONN Sonnet BioTherapeutics Net earnings per share for the last 12 months (07/04/2022 - 12/13/2025)

Summary analytical data breakdowns for Sonnet BioTherapeutics (SONN)

Fundamental valuation:SONN - sonnetbio.com
Flagship merchandise of Sonnet BioTherapeutics Holdings Inc.

Analyzing the EPS TTM history allows us to assess the financial stability of the biotechnology sector. This metric reflects the adjusted net income per share over a trailing twelve-month period, eliminating reporting lags. It demonstrates a company's ability to service debt during a period of high Fed rates. For Sonnet BioTherapeutics (SONN), this indicator determines the investment efficiency of its targeted drug delivery platform. The earnings trend confirms the viability of the selective tumor therapy model.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Immatics Corp IMTX|Xencor Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|LYEL (lyell.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|MAIA Biotechnology - Earnings per share for the trailing year|LIMN (liminatuspharma.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) lavatherapeutics.com|Earnings per share for the last twelve months NextCure (NXTC)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics (SNSE) - Net earnings per one share for the last twelve months|TOVX: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Gritstone bio (GRTS)|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune, Inc. (NEXI)|Earnings per share for the last twelve months turnstonebio.com|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)